Abstract
1FC2.1 Exon skipping and dystrophin restoration in Duchenne Muscular Dystrophy patients after systemic phosphorodiamidate morpholino oligomer treatment S. Cirak1 *, V. Arechavala-Gomeza1, M. Guglieri2, L. Feng1, S. Torelli1, K. Anthony1, M.E. Garralda3, D.J. Wells4, G. Dickson5, M.J.A. Wood6, S. Wilton7, V. Straub2, S.B. Shrewsbury8, C. Sewry9, J.E. Morgan1, K. Bushby2, F. Muntoni1. 1UCL Institute of Child Health The Dubowitz Neuromuscular Centre, London, United Kingdom, 2Institute of Human Genetics, Newcastle University, Newcastle, United Kingdom, 3Academic Unit of Child and Adolescent Psychiatry, Imperial College St Mary’s Campus, London, United Kingdom, 4Royal Veterinary College, London, United Kingdom, 5Royal Holloway University of London, United Kingdom, 6Department of Physiology, Anatomy and Genetics, University of Oxford, United Kingdom, 7Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Perth, Australia, 8AVI BioPharma, Bothell, WA, United States, 9Centre for Inherited Neuromuscular Disorders, Robert Jones and Agnes Hunt NHS Trust, Oswestry, United Kingdom
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
